Literature DB >> 15858043

Residues in the murine leukemia virus capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions.

Adeline Lassaux1, Marc Sitbon, Jean-Luc Battini.   

Abstract

We identified new residues within a 101-amino-acid stretch of the murine leukemia virus capsid that differentially modulate resistance and susceptibility to the mouse Fv1 and human Ref1 genes. Among these residues, aspartate 92 and histidine 117 are both required for Fv1(b) resistance, whereas the latter is sufficient to confer Ref1 resistance.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15858043      PMCID： PMC1091700          DOI： 10.1128/JVI.79.10.6560-6564.2005

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  34 in total

1.  An intracellular block to primate lentivirus replication.

Authors:  Jonathan P Stoye
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells.

Authors:  Christopher M Owens; Peter C Yang; Heinrich Göttlinger; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Species-specific, postentry barriers to primate immunodeficiency virus infection.

Authors:  W Hofmann; D Schubert; J LaBonte; L Munson; S Gibson; J Scammell; P Ferrigno; J Sodroski
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  A single amino acid change in the murine leukemia virus capsid gene responsible for the Fv1(nr) phenotype.

Authors:  Y T Jung; C A Kozak
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors.

Authors:  Greg J Towers; Theodora Hatziioannou; Simone Cowan; Stephen P Goff; Jeremy Luban; Paul D Bieniasz
Journal:  Nat Med       Date:  2003-08-03       Impact factor: 53.440

6.  Restriction of multiple divergent retroviruses by Lv1 and Ref1.

Authors:  Theodora Hatziioannou; Simone Cowan; Stephen P Goff; Paul D Bieniasz; Greg J Towers
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

Review 7.  Restriction factors: a defense against retroviral infection.

Authors:  Paul D Bieniasz
Journal:  Trends Microbiol       Date:  2003-06       Impact factor: 17.079

8.  Restriction of lentivirus in monkeys.

Authors:  Caroline Besnier; Yasuhiro Takeuchi; Greg Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-01       Impact factor: 11.205

9.  Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism.

Authors:  Simone Cowan; Theodora Hatziioannou; Tshaka Cunningham; Mark A Muesing; Heinrich G Gottlinger; Paul D Bieniasz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-01       Impact factor: 11.205

10.  Characterization of murine leukemia virus restriction in mammals.

Authors:  Caroline Besnier; Laura Ylinen; Benjamin Strange; Adrian Lister; Yasuhiro Takeuchi; Stephen P Goff; Greg J Towers
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103
View more
  21 in total

1.  Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription.

Authors:  Luca D Passerini; Zuzana Keckesova; Greg J Towers
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

2.  The specificity of TRIM5 alpha-mediated restriction is influenced by its coiled-coil domain.

Authors:  Pierre V Maillard; Gabriela Ecco; Millán Ortiz; Didier Trono
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Myocyte enhancer factor 2c, an osteoblast transcription factor identified by dimethyl sulfoxide (DMSO)-enhanced mineralization.

Authors:  Alexandre S Stephens; Sebastien R Stephens; Carl Hobbs; Deitmar W Hutmacher; Desa Bacic-Welsh; Maria Ann Woodruff; Nigel A Morrison
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

4.  Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction.

Authors:  Pierre V Maillard; Vincent Zoete; Olivier Michielin; Didier Trono
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

5.  The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.

Authors:  Michael J Metzger; Christiana J Holguin; Ramon Mendoza; A Dusty Miller
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

6.  Novel postentry resistance to AKV ecotropic mouse gammaretroviruses in the African pygmy mouse, Mus minutoides.

Authors:  Yuhe Yan; Christine A Kozak
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  The Tom1L1-clathrin heavy chain complex regulates membrane partitioning of the tyrosine kinase Src required for mitogenic and transforming activities.

Authors:  Guillaume Collin; Mélanie Franco; Valérie Simon; Christine Bénistant; Serge Roche
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

8.  Interplay between primary familial brain calcification-associated SLC20A2 and XPR1 phosphate transporters requires inositol polyphosphates for control of cellular phosphate homeostasis.

Authors:  Uriel López-Sánchez; Sandrine Tury; Gaël Nicolas; Miranda S Wilson; Snejana Jurici; Xavier Ayrignac; Valérie Courgnaud; Adolfo Saiardi; Marc Sitbon; Jean-Luc Battini
Journal:  J Biol Chem       Date:  2020-05-11       Impact factor: 5.157

9.  Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses.

Authors:  Torsten Schaller; Laura M J Ylinen; Benjamin L J Webb; Shalene Singh; Greg J Towers
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

10.  Characterization of an amino-terminal dimerization domain from retroviral restriction factor Fv1.

Authors:  Kate N Bishop; Gulnahar B Mortuza; Steven Howell; Melvyn W Yap; Jonathan P Stoye; Ian A Taylor
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.